Trial Profile
A Phase I/II Dose Escalation Trial of HDAC Inhibitor Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tefinostat (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jun 2019 Trial has been discontinued in UK, according to European Clinical Trials Database record.
- 19 Dec 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 19 Dec 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.